{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:36:56Z","timestamp":1770370616070,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,7,28]],"date-time":"2013-07-28T00:00:00Z","timestamp":1374969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40263-013-0095-5","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T13:56:27Z","timestamp":1374933387000},"page":"829-840","source":"Crossref","is-referenced-by-count":53,"title":["Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder"],"prefix":"10.1007","volume":"27","author":[{"given":"Tobias","family":"Banaschewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Soutullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Lecendreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hodgkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Adeyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"A. Squires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,28]]},"reference":[{"key":"95_CR1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942\u20138.","journal-title":"Am J Psychiatry"},{"key":"95_CR2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1741-7015-9-72","volume":"9","author":"KM Antshel","year":"2011","unstructured":"Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;9:72.","journal-title":"BMC Med"},{"key":"95_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S1092852900013869","volume":"13","author":"MA Stein","year":"2008","unstructured":"Stein MA. Impairment associated with adult ADHD. CNS Spectr. 2008;13:9\u201311.","journal-title":"CNS Spectr"},{"key":"95_CR4","volume-title":"International statistical classification of diseases and related health problems, ICD-10","author":"World Health Organisation","year":"2010","unstructured":"World Health Organisation. International statistical classification of diseases and related health problems, ICD-10. 4th ed. Geneva: World Health Organisation; 2010.","edition":"4"},{"key":"95_CR5","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). Washington, DC: The Press; 2000."},{"key":"95_CR6","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Arlington: American Psychiatric Publishing; 2013."},{"key":"95_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-3-1","volume":"3","author":"E Parens","year":"2009","unstructured":"Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"95_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00787-009-0046-3","volume":"19","author":"M Danckaerts","year":"2010","unstructured":"Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit\/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83\u2013105.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"95_CR9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/11537450-000000000-00000","volume":"24","author":"D Coghill","year":"2010","unstructured":"Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843\u201366.","journal-title":"CNS Drugs"},{"key":"95_CR10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.euroneuro.2010.11.007","volume":"21","author":"D Coghill","year":"2011","unstructured":"Coghill D. Pragmatic measures in paediatric psychopharmacology\u2013are we getting it right? Eur Neuropsychopharmacol. 2011;21:571\u201383.","journal-title":"Eur Neuropsychopharmacol"},{"key":"95_CR11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2107B","volume":"128","author":"American Academy of Pediatrics","year":"2011","unstructured":"American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007\u201322.","journal-title":"Pediatrics"},{"key":"95_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00787-006-0549-0","volume":"15","author":"T Banaschewski","year":"2006","unstructured":"Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476\u201395.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"95_CR13","unstructured":"Deutsche Gesellschaft f\u00fcr Kinder- und Jugendpsychiatrie und Psychotherapie. Hyperkinetische St\u00f6rungen (F90). In: Deutsche Gesellschaft f\u00fcr Kinder- und Jugendpsychiatrie und Psychotherapie, editor. Leitlinien zur Diagnostik und Therapie von psychischen St\u00f6rungen in S\u00e4uglings, Kindes- und Judendalter. \u00fcberarbeitete Auflage ed. Cologne: Deutscher \u00c4rtze Verlag; 2007."},{"key":"95_CR14","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1097\/00004583-200210000-00003","volume":"41","author":"LL Greenhill","year":"2002","unstructured":"Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S\u201349S.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR15","unstructured":"National Collaborating Centre for Mental Health (commissioned by the National Institute for Health & Clinical Excellence). Diagnosis and management of ADHD in children, young people and adults. National clinical practice guideline Number 72. London: The British Psychological Society and The Royal College of Psychiatrists; 2009."},{"key":"95_CR16","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperactivity disorders in children and young people\u2014a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2009."},{"issue":"Suppl 1","key":"95_CR17","first-page":"I7","volume":"13","author":"E Taylor","year":"2004","unstructured":"Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder\u2014first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I7\u201330.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"95_CR18","unstructured":"The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 3rd ed. Toronto: CADDRA; 2011."},{"key":"95_CR19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450\u201363.","journal-title":"Clin Ther"},{"key":"95_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364\u201373.","journal-title":"J Clin Psychiatry"},{"key":"95_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"95_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-9081-6-34","volume":"6","author":"T Wigal","year":"2010","unstructured":"Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.","journal-title":"Behav Brain Funct"},{"key":"95_CR24","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;. doi: 10.1016\/j.euroneuro.2012.11.012 .","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 1","key":"95_CR25","doi-asserted-by":"crossref","first-page":"I63","DOI":"10.1007\/s00787-006-1009-6","volume":"15","author":"AW Riley","year":"2006","unstructured":"Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I63\u201371.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"95_CR26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/cap.2008.0166","volume":"19","author":"M Maziade","year":"2009","unstructured":"Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit\/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709\u201318.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cap.2011.0018","volume":"21","author":"MA Stein","year":"2011","unstructured":"Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR28","unstructured":"Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical Manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001."},{"key":"95_CR29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.mlr.0000114909.33878.ca","volume":"42","author":"AW Riley","year":"2004","unstructured":"Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care. 2004;42:210\u201320.","journal-title":"Med Care"},{"key":"95_CR30","unstructured":"The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale\u2014Parent Report (WFIRS-P); 2000. http:\/\/www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011WFIRS_P.pdf (Accessed 18 Mar 2013)."},{"key":"95_CR31","unstructured":"The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale (WFIRS) instructions; 2000 http:\/\/www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011WFIRSInstructions.pdf (Accessed 18 Mar 2013)."},{"key":"95_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112:155\u20139.","journal-title":"Psychol Bull"},{"key":"95_CR33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12402-011-0066-y","volume":"3","author":"A Schacht","year":"2011","unstructured":"Schacht A, Escobar R, Wagner T, Wehmeier PM. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. Atten Defic Hyperact Disord. 2011;3:335\u201349.","journal-title":"Atten Defic Hyperact Disord"},{"key":"95_CR34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","volume":"19","author":"G Dell\u2019Agnello","year":"2009","unstructured":"Dell\u2019Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009;19:822\u201334.","journal-title":"Eur Neuropsychopharmacol"},{"key":"95_CR35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/cap.2008.0109","volume":"19","author":"R Escobar","year":"2009","unstructured":"Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, et al. Evaluation of patients\u2019 and parents\u2019 quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:253\u201363.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1185\/030079906X167309","volume":"23","author":"S Prasad","year":"2007","unstructured":"Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit\/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23:379\u201394.","journal-title":"Curr Med Res Opin"},{"key":"95_CR37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00787-009-0031-x","volume":"18","author":"P Svanborg","year":"2009","unstructured":"Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Schacht A, Kadesjo B. Atomoxetine improves patient and family coping in attention deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:725\u201335.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"990\u20131002","key":"95_CR38","first-page":"e2","volume":"51","author":"JA Doshi","year":"2012","unstructured":"Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, et al. Economic impact of childhood and adult attention-deficit\/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(990\u20131002):e2.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2007-964908","volume":"29","author":"AF San Juan","year":"2008","unstructured":"San Juan AF, Chamorro-Vina C, Mate-Munoz JL, Fernandez del Valle M, Cardona C, Hernandez M, et al. Functional capacity of children with leukemia. Int J Sports Med. 2008;29:163\u20137.","journal-title":"Int J Sports Med"},{"key":"95_CR40","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2004040258","volume":"16","author":"AC Gerson","year":"2005","unstructured":"Gerson AC, Riley A, Fivush BA, Pham N, Fiorenza J, Robertson J, et al. Assessing health status and health care utilization in adolescents with chronic kidney disease. J Am Soc Nephrol. 2005;16:1427\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"95_CR41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.juro.2007.04.008","volume":"178","author":"JL Dodson","year":"2007","unstructured":"Dodson JL, Diener-West M, Gerson AC, Kaskel FJ, Furth SL. An assessment of health related quality of life using the child health and illness profile-adolescent edition in adolescents with chronic kidney disease due to underlying urological disorders. J Urol. 2007;178:660\u20135.","journal-title":"J Urol"},{"key":"95_CR42","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.juro.2008.03.121","volume":"180","author":"JL Dodson","year":"2008","unstructured":"Dodson JL, Furth SL, Hsiao CJ, Diener-West M, Levey EB, Wu AW, et al. Health related quality of life in adolescents with abnormal bladder function: an assessment using the Child Health and Illness Profile-Adolescent Edition. J Urol. 2008;180:1846\u201351.","journal-title":"J Urol"},{"key":"95_CR43","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00467-009-1175-0","volume":"24","author":"I Riano-Galan","year":"2009","unstructured":"Riano-Galan I, Malaga S, Rajmil L, Ariceta G, Navarro M, Loris C, et al. Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatr Nephrol. 2009;24:1561\u20138.","journal-title":"Pediatr Nephrol"},{"key":"95_CR44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jpeds.2004.06.043","volume":"145","author":"SO Okelo","year":"2004","unstructured":"Okelo SO, Wu AW, Krishnan JA, Rand CS, Skinner EA, Diette GB. Emotional quality-of-life and outcomes in adolescents with asthma. J Pediatr. 2004;145:523\u20139.","journal-title":"J Pediatr"},{"key":"95_CR45","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1542\/peds.99.2.e1","volume":"99","author":"CB Forrest","year":"1997","unstructured":"Forrest CB, Starfield B, Riley AW, Kang M. The impact of asthma on the health status of adolescents. Pediatrics. 1997;99:E1.","journal-title":"Pediatrics"},{"key":"95_CR46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1753-2000-4-30","volume":"4","author":"PM Wehmeier","year":"2010","unstructured":"Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V. Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit\/hyperactivity disorder core symptoms: meta-analysis of five atomoxetine trials. Child Adolesc Psychiatry Ment Health. 2010;4:30.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"95_CR47","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4088\/JCP.08m04902pur","volume":"71","author":"SV Faraone","year":"2010","unstructured":"Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754\u201363.","journal-title":"J Clin Psychiatry"},{"key":"95_CR48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1469-7610.2009.02008.x","volume":"50","author":"D Coghill","year":"2009","unstructured":"Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J. Practitioner review: quality of life in child mental health\u2014conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50:544\u201361.","journal-title":"J Child Psychol Psychiatry"},{"key":"95_CR49","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11136-011-9992-6","volume":"21","author":"MD Estrada","year":"2012","unstructured":"Estrada MD, Rajmil L, Herdman M, Serra-Sutton V, Tebe C, Alonso J, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile Child-Edition\/Child Report Form (CHIP-CE\/CRF). Qual Life Res. 2012;21:909\u201314.","journal-title":"Qual Life Res"},{"key":"95_CR50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1477-7525-8-78","volume":"8","author":"MD Estrada","year":"2010","unstructured":"Estrada MD, Rajmil L, Serra-Sutton V, Tebe C, Alonso J, Herdman M, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile (CHIP) Child-Edition, Parent Report Form (CHIP-CE\/PRF). Health Qual Life Outcomes. 2010;8:78.","journal-title":"Health Qual Life Outcomes"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0095-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0095-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:22Z","timestamp":1551204742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0095-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,28]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0095-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,28]]}}}